139986-06-4

Upstream product

• 100-39-0 benzyl bromide 
• 139986-04-2 (S)-pyrrolidine-1,3-dicarboxylic acid 3-benzyl ester 1-tert-butyl ester 
• 76-05-1 trifluoroacetic acid 
• 140148-70-5 (S)-1-N-boc-β-proline 

Downstream Products

• 1412978-82-5 benzyl (S)-1-ethylpyrrolidine-3-carboxylate 
• 1412978-80-3 (S)-1-ethylpyrrolidine-3-carboxylic acid 
• 1621065-21-1 (S)-benzyl 1-((2-(((trans)-4-(tert-butyl)cyclohexyl)oxy)-4-methylnaphthalen-1-yl)methyl)pyrrolidine-3-carboxylate 
• 1621065-20-0 (S)-1-((2-(((trans)-4-(tert-butyl)cyclohexyl)oxy)-4-methylnaphthalen-1-yl)methyl)pyrrolidine-3-carboxylic acid 
• 1412978-78-9 methyl (1aRS,7bSR)-5-(2-{[((S)-1-ethylpyrrolidine-3-carbonyl)amino]methyl}-4-fluoro-benzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylate 
• 1412975-25-7 (1aRS,7bSR)-5-(2-{[((S)-1-ethylpyrrolidine-3-carbonyl)amino]methyl}-4-fluoro-benzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid 

Relevant academic research and scientific papers

METHODS OF TREATING LIVER DISEASES

The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2.

S1P MODULATING AGENTS

Compounds of formula (I) can modulate the activity of one or more S 1P receptors. Sphingosine 1-phosphate (S IP) is a lysophospholipid mediator that evokes a variety of cellular responses by stimulation of five members of the endothelial cell differentiation gene (EDG) receptor family, namely S1P1, S1P2, S1P3, S1P4, and S1P5 (formerly EDG1, EDG5, EDG3, EDG6 and EDG8). The EDG receptors are G-protein coupled receptors (GPCRs) and on stimulation propagate second messenger signals via activation of heterotrimeric G-protein alpha (Ga.) subunits and beta-gamma (G()y) dimers.

PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.